Plus Therapeutics (NASDAQ:PSTV – Get Free Report) released its earnings results on Thursday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.43), FiscalAI reports. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The firm had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.11 million.
Plus Therapeutics Stock Down 0.5%
Shares of NASDAQ:PSTV traded down $0.02 during midday trading on Friday, reaching $3.68. The company’s stock had a trading volume of 109,031 shares, compared to its average volume of 116,506. The business has a 50 day moving average price of $4.12 and a 200 day moving average price of $5.44. Plus Therapeutics has a 1 year low of $2.90 and a 1 year high of $23.42. The firm has a market cap of $25.33 million, a price-to-earnings ratio of -1.60 and a beta of 1.40.
Analysts Set New Price Targets
Several brokerages recently issued reports on PSTV. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Friday, July 17th. Ascendiant Capital Markets cut their price objective on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $56.40.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Plus Therapeutics by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares during the period. Jane Street Group LLC purchased a new position in Plus Therapeutics in the 4th quarter worth approximately $525,000. Virtu Financial LLC acquired a new stake in Plus Therapeutics in the fourth quarter valued at approximately $254,000. State Street Corp grew its position in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after acquiring an additional 127,000 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Plus Therapeutics during the fourth quarter valued at approximately $127,000. 3.28% of the stock is owned by hedge funds and other institutional investors.
Plus Therapeutics Company Profile
Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.
The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.
Featured Articles
- Five stocks we like better than Plus Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
